HOLOGIC INC: directors' dealings · United States · SEC (Form 4)

About HOLOGIC INC

Hologic Inc. (ticker: HOLX) is a U.S.-based medical technology company focused on women’s health and formerly listed on the NASDAQ market in the United States. Headquartered in Marlborough, Massachusetts, Hologic was founded in 1985 and has built its franchise around clinically proven technologies that support screening, diagnosis, and treatment across women’s health pathways. Its business model combines recurring consumables, installed equipment, and innovation-led product upgrades, making it a differentiated medtech platform rather than a pure-play diagnostics company. ([hologic.com](https://www.hologic.com/about?utm_source=openai)) Hologic reports its operations through four principal segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment includes molecular testing and cytology solutions used in disease screening and detection, with particular strength in cervical health and sexual health testing. Breast Health is one of the company’s core pillars, spanning mammography systems, breast biopsy tools, localization technologies, and related imaging solutions used from screening through treatment. GYN Surgical includes products designed to address gynecologic conditions such as abnormal uterine bleeding, while Skeletal Health covers bone-densitometry and related imaging solutions. This multi-segment structure gives Hologic a broad clinical footprint and helps balance growth across hospital, outpatient, and women’s health settings. ([fintel.io](https://fintel.io/doc/sec-hologic-inc-859737-10k-2025-november-18-20410-6130?utm_source=openai)) From a competitive standpoint, Hologic holds a meaningful position in women’s health diagnostics and breast imaging, supported by recognized brands, a substantial installed base, and a global commercial network. The company says it operates in 36 countries and holds more than 4,100 patents, which underscores the depth of its intellectual property and the barriers to entry in several of its end markets. Its competitive strategy centers on precision, workflow efficiency, and clinical confidence, with increasing emphasis on AI-enabled mammography and next-generation biopsy solutions. ([hologic.com](https://www.hologic.com/about?utm_source=openai)) Recent developments have been especially important. In October 2025, Hologic announced a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, and the deal was subsequently approved and completed in 2026, taking the company private. The company also received CE marking in February 2025 for its Affirm Contrast Biopsy software, and it continued expanding digital pathology capabilities later in 2025. Taken together, these events highlight a company that remains strategically focused on women’s health innovation while entering a new ownership structure. ([investor.hologic.com](https://investor.hologic.com/press-releases/press-release-details/2025/Hologic-to-be-Acquired-by-Blackstone-and-TPG-for-up-to-79-per-Share/default.aspx?utm_source=openai))